Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Syngene International...

    Syngene International Q1 net profit rises 9 percent to Rs 72 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-25T09:30:22+05:30  |  Updated On 25 July 2019 9:30 AM IST
    Syngene International Q1 net profit rises 9 percent to Rs 72 crore

    The company had posted a net profit of Rs 66.2 crore for the same period previous fiscal, Syngene International said in a BSE filing.


    New Delhi: Contract research and manufacturing firm Syngene International on July 24 reported a 9 per cent rise in its consolidated net profit to Rs 72 crore for the first quarter ended June 30. The company had posted a net profit of Rs 66.2 crore for the same period previous fiscal, Syngene International said in a BSE filing.


    The company's consolidated total income rose to Rs 441.4 crore for the quarter under consideration as against Rs 424.8 crore in the corresponding period a year ago.


    Read Also: Syngene collaborates with BIRAC to set up Centre for Advanced Protein Studies


    "The quarter saw continued steady growth in the discovery services and dedicated R&D centres verticals. Growth in development services and manufacturing services was impacted by project phasing and is expected to pick up through the remainder of the year," Syngene International CEO Jonathan Hunt said.


    Mahesh Bhalgat was appointed as Chief Operating Officer with effect from July 1, 2019, the company said.


    Read Also: Syngene International records Q4 revenue up 30 percent to Rs 555 crore

    Bioconbse filingJonathan HuntKiran ShawMahesh Bhalgatnet profitpharmapharma newspharma news indiaSyngeneSyngene Internationalsyngene quarterly income
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok